Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
11331
Shown on this page
12
Current sort
Recently updated
Location scope
Cleveland, OH
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Cleveland, Ohio. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 229–240 of 11,331 matching trials in Cleveland, OH.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 2 Interventional

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069
View directory record Official record
Conditions
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
180 Days to 22 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
108
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 85 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting Phase 3 Interventional

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126
View directory record Official record
Conditions
Melanoma, Cutaneous Malignant, Mucosal Melanoma
Interventions
IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
Biological · Drug
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Active, not recruiting Phase 2 Interventional Results available

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

NCT03994796
View directory record Official record
Conditions
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
435
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting Phase 2 Interventional

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

NCT07219043
View directory record Official record
Conditions
Microvascular Inflammation
Interventions
Felzartamab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 74 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting Not applicable Interventional

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

NCT03242642
View directory record Official record
Conditions
Mitral Valve Regurgitation
Interventions
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2036
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting Phase 3 Interventional

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
158
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB161734, Placebo, Investigator's choice of chemotherapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
69
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

NCT07282665
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C.difficile vaccine, Saline Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
32,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
142
States / cities
Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting Phase 2 Interventional

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830
View directory record Official record
Conditions
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions
NEU-411, Placebo
Drug · Other
Lead sponsor
Neuron23 Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
45
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Active, not recruiting Not applicable Interventional

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring

NCT05587972
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma
Interventions
survey
Other
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting Phase 1 Interventional

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT07441694
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCA036978, Standard disease-directed therapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
23
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Active, not recruiting Phase 3 Interventional

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

NCT07363720
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
Interventions
TAK-861, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
11
States / cities
Redwood City, California • Brandon, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 10:52 PM EST